UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

ClinicoEconomics and outcomes research, 2024-08, Vol.16, p.567-579

2024

Volltextzugriff (PDF)

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

Circulation Cardiovascular quality and outcomes, 2018-01, Vol.11 (1), p.e003939-e003939

2018

Volltextzugriff (PDF)

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2316-2323

2023

Volltextzugriff (PDF)

Barriers and solutions to improve access for chimeric antigen receptor therapies

Immunotherapy, 2022-06, Vol.14 (9), p.741-753

2022

Volltextzugriff (PDF)

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

Journal of managed care & specialty pharmacy, 2024-07, p.1-11

2024

Volltextzugriff (PDF)

Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries

Journal of managed care & specialty pharmacy, 2021-10, Vol.27 (10), p.1457-1468

2021

Volltextzugriff (PDF)

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

Value in health, 2020-02, Vol.23 (2), p.209-216

2020

Volltextzugriff (PDF)

CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S277-S278

2022

Volltextzugriff (PDF)

Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-02, Vol.8 (2), p.507-515.e10

2020

Volltextzugriff (PDF)

Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia

Cancer medicine (Malden, MA), 2024-01, Vol.13 (2), p.e6953-n/a

2024

Volltextzugriff (PDF)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

Open forum infectious diseases, 2022-10, Vol.9 (10), p.ofac435-ofac435

2022

Volltextzugriff (PDF)

P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING

HemaSphere, 2023-08, Vol.7 (S3), p.e7912542-n/a

2023

Volltextzugriff (PDF)

Novel elements of value in the context of oncology

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18823-e18823

2021

Volltextzugriff (PDF)

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Blood, 2023-11, Vol.142 (Supplement 1), p.2326-2326

2023

Volltextzugriff (PDF)

Valuing treatment in oncology: embracing a broader notion of value

Journal of managed care & specialty pharmacy, 2022-03, Vol.28 (3), p.362-368

2022

Volltextzugriff (PDF)

Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries

Blood, 2022-11, Vol.140 (Supplement 1), p.5041-5042

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2022-11, Vol.140 (Supplement 1), p.10814-10815

2022

Volltextzugriff (PDF)

647: REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-157-S-157

2022

Volltextzugriff (PDF)

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Blood, 2023-11, Vol.142 (Supplement 1), p.5085-5085

2023

Volltextzugriff (PDF)

S900 Real World Treatment (Tx) Patterns and Healthcare Costs Among U.S. Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S424-S424

2021

Volltextzugriff (PDF)

Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Blood, 2022-11, Vol.140 (Supplement 1), p.7939-7940

2022

Volltextzugriff (PDF)

Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Blood, 2022-11, Vol.140 (Supplement 1), p.5043-5044

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis

Clinical lymphoma, myeloma and leukemia, 2024-06

2024

Volltextzugriff (PDF)

Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs

Leukemia & lymphoma, 2023-11, Vol.ahead-of-print (ahead-of-print), p.1-13

2023

Volltextzugriff (PDF)

Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma

Future oncology (London, England), 2024-02, Vol.20 (6), p.317-328

2024

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(49)
Dissertationen
(1)

Sprache

Englisch
(50)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

Barriers and solutions to improve access for chimeric antigen receptor therapies

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population

Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

P1695: REAL‐WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX IN THE RELAPSED/REFRACTORY SETTING

Novel elements of value in the context of oncology

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Valuing treatment in oncology: embracing a broader notion of value

Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries

Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)

647: REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

S900 Real World Treatment (Tx) Patterns and Healthcare Costs Among U.S. Commercially Insured Adults Initiating Biologics for Ulcerative Colitis (UC)

Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study

Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status

Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis

Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs

Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma

Suchergebnisse filtern